Based on the preclinical investigations and due to the poor efficacy of anti-CTLA-4 monotherapy shown in clinical trials, these therapeutics are further tested in combination with other IC inhibitors, chemotherapy, or radiotherapy to improve the treatment outcome of breast cancer patients [197]. The gene discussed is CTLA4; the disease is breast cancer.